{"id":"imiquimod-3-75-cream","safety":{"commonSideEffects":[{"rate":null,"effect":"Local skin irritation (erythema, erosion, flaking)"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Burning sensation"},{"rate":null,"effect":"Flu-like symptoms"}]},"_chembl":{"chemblId":"CHEMBL1282","moleculeType":"Small molecule","molecularWeight":"240.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Imiquimod binds to TLR7 on immune cells, triggering production of interferon-alpha and other cytokines that enhance local immune activation. This immune stimulation promotes clearance of abnormal skin cells and has antiviral and anti-tumor properties. The 3.75% cream formulation is designed for topical application to affected skin areas.","oneSentence":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:07.361Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis"},{"name":"Basal cell carcinoma"},{"name":"Genital warts"}]},"trialDetails":[{"nctId":"NCT03943407","phase":"NA","title":"Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch","status":"WITHDRAWN","sponsor":"Aalborg University","startDate":"2019-11-01","conditions":"Itch","enrollment":""},{"nctId":"NCT04842422","phase":"PHASE4","title":"Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2021-04-16","conditions":"Actinic Keratoses","enrollment":48},{"nctId":"NCT02301494","phase":"NA","title":"Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma","status":"WITHDRAWN","sponsor":"Rochester General Hospital","startDate":"2020-04","conditions":"Mycosis Fungoides","enrollment":""},{"nctId":"NCT03914417","phase":"PHASE2","title":"Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2013-01","conditions":"Actinic Keratosis","enrollment":21},{"nctId":"NCT01686152","phase":"PHASE3","title":"Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2012-09","conditions":"Actinic Keratosis","enrollment":589},{"nctId":"NCT01203878","phase":"PHASE4","title":"Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy","status":"TERMINATED","sponsor":"Tennessee Clinical Research Center","startDate":"2010-09","conditions":"Actinic Keratosis","enrollment":21},{"nctId":"NCT01788007","phase":"PHASE1","title":"Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2013-01","conditions":"Actinic Keratosis","enrollment":443},{"nctId":"NCT01413763","phase":"PHASE4","title":"Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis","status":"UNKNOWN","sponsor":"Medicis Global Service Corporation","startDate":"2011-07","conditions":"Actinic Keratosis","enrollment":50},{"nctId":"NCT01502020","phase":"NA","title":"A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses","status":"COMPLETED","sponsor":"Actavis Mid-Atlantic LLC","startDate":"2011-02","conditions":"Actinic Keratoses","enrollment":410},{"nctId":"NCT00735462","phase":"PHASE3","title":"Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2008-08","conditions":"Genital Warts","enrollment":511},{"nctId":"NCT01229319","phase":"PHASE4","title":"Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses","status":"UNKNOWN","sponsor":"Frankel, Amylynne, M.D.","startDate":"2010-10","conditions":"Actinic Keratosis","enrollment":20},{"nctId":"NCT00674739","phase":"PHASE3","title":"Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2008-05","conditions":"Genital Warts","enrollment":470},{"nctId":"NCT00894647","phase":"PHASE3","title":"Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2009-05","conditions":"Actinic Keratosis","enrollment":247},{"nctId":"NCT00605176","phase":"PHASE3","title":"Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2008-01","conditions":"Actinic Keratoses","enrollment":479},{"nctId":"NCT00603798","phase":"PHASE3","title":"Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2008-01","conditions":"Actinic Keratosis","enrollment":490}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Imiquimod 3.75% Cream","genericName":"Imiquimod 3.75% Cream","companyName":"Medical University of Graz","companyId":"medical-university-of-graz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions. Used for Actinic keratosis, Basal cell carcinoma, Genital warts.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}